Thrivent Financial for Lutherans Increases Holdings in Tema Oncology ETF $CANC

Thrivent Financial for Lutherans lifted its holdings in Tema Oncology ETF (NASDAQ:CANC) by 658.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 957,475 shares of the company’s stock after acquiring an additional 831,281 shares during the period. Thrivent Financial for Lutherans owned 0.37% of Tema Oncology ETF worth $23,673,000 at the end of the most recent quarter.

Separately, Banque Transatlantique SA purchased a new stake in Tema Oncology ETF during the first quarter valued at approximately $39,000.

Tema Oncology ETF Stock Performance

Shares of Tema Oncology ETF stock opened at $34.73 on Wednesday. The stock has a market cap of $96.90 million, a price-to-earnings ratio of 20.39 and a beta of 1.00. The stock has a 50 day moving average price of $32.53 and a 200-day moving average price of $28.54. Tema Oncology ETF has a one year low of $20.10 and a one year high of $36.14.

Tema Oncology ETF Announces Dividend

The company also recently disclosed an annual dividend, which was paid on Thursday, December 11th. Shareholders of record on Wednesday, December 10th were given a dividend of $0.0196 per share. The ex-dividend date was Wednesday, December 10th. This represents a yield of 6.0%.

About Tema Oncology ETF

The Tema Oncology ETF (CANC) is an exchange-traded fund that mostly invests in health care equity. The fund is actively managed, investing in stocks of companies focused on cancer treatment and management from issuers all around the world. The fund uses a bottom-up approach to select pioneering companies at perceived attractive valuations CANC was launched on Aug 15, 2023 and is issued by Tema.